We support life-science coalitions by identifying impactful goals and crafting efficient, results-focused strategies.

We manage the launch and development of groups of companies with common goals and a health-care specific perspective.

The Antimicrobials Working Group (AWG) was founded in 2012 with the vision of utilizing collective power to improve the regulatory, investment, and commercial environment for emerging infectious disease companies. Today, AWG is comprised of biopharmaceutical companies and in six years of work, the coalition has taken significant strides towards addressing the regulatory and commercial challenges facing antimicrobial developers, and is currently focusing on enhanced reimbursement, R&D tax credits, and market entry rewards for antimicrobial and diagnostic device companies.


The Microbiome Therapeutics Innovation Group (MTIG) is a coalition of companies leading the research and development of FDA-approved microbiome therapeutics and microbiome-based products to address unmet medical needs, improve clinical outcomes, and reduce health care costs. The human microbiome is a new frontier of medical innovation that has the potential to benefit patients suffering from numerous diseases afflicting millions of patients, and consuming billions of dollars of healthcare resources. Areas of research include infectious diseases, gastrointestinal disorders, cancers, mental or psychological diseases, autoimmune diseases and more. MTIG is committed to working with stakeholders who share in our mission and seek tangible policy and regulatory solutions in the emerging microbiome arena. Through a collective voice, the MTIG membership works together to enhance the regulatory, investment, and commercial environment to accelerate microbiome therapeutic product development and enable the field to reach its potential to benefit patients.

The Coalition for Access to Prenatal Screening (CAPS) is a collaborative alliance of  leading genetic testing companies in the United States that seeks to improve access to state-of-the-art prenatal screening using cell-free DNA (cfDNA)-based noninvasive prenatal screening (NIPS) for all pregnant women who choose to pursue aneuploidy screening – regardless of their risk factors, income, age or geographic location.